Login to Your Account



Cytokinetics Shares Drop 22% Despite 'Encouraging' Data

By Tom Wall


Tuesday, December 14, 2010
Cytokinetics Inc.'s shares (NASDAQ:CYTK) were down 65 cents, or 22.2 percent, to close at $2.28 Monday despite "encouraging" results in amyotrophic lateral sclerosis (ALS) patients from a Phase IIa evidence-of-effect trial of CK-2017357, a fast skeletal muscle troponin activator and the lead drug candidate in the company's skeletal muscle contractility program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription